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Abstract  
Background 
Due to the restrictive nature of a gluten-free diet, celiac patients are looking for 
alternative therapies. While drug-development programs include gluten challenges,  
knowledge regarding the duration of gluten challenge and gluten dosage is insufficient.  
We challenged adult celiac patients with gluten with a view to assessing the amount 
needed to cause some small-bowel mucosal deterioration. 
Methods 
Twenty-five celiac disease adults were challenged with low (1-3 g) or moderate (3-5g) 
doses of gluten daily for 12 weeks. Symptoms, small-bowel morphology, densities of  
CD3+ intraepithelial lymphocytes (IELs) and celiac serology were determined. 
Results 
Both moderate and low amounts of gluten induced small-bowel morphological damage in 
67% of celiac patients. Moderate gluten doses also triggered mucosal inflammation and 
more gastrointestinal symptoms leading to premature withdrawals in seven cases. In 22% 
of those who developed significant small- intestinal damage, symptoms remained absent. 
Celiac antibodies seroconverted in 43% of the patients. 
Conclusions 
Low amounts of gluten can also cause significant mucosal deterioration in the majority of 
the patients. As there are always some celiac disease patients who will not respond within 
these conditions, sample sizes must be sufficiently large to attain to statistical power in 
analysis. 
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Background 
Celiac disease is an autoimmune-like systemic disorder in genetically susceptible 
individuals, perpetuated by daily ingested gluten cereals wheat, rye and barley and with 
manifestations in the small- intestinal mucosa and in organs outside the gut.  The gold 
standard for celiac disease diagnosis is the finding of gluten-induced small-intestinal 
mucosal injury [1,2]. The mucosa will heal upon introduction of a gluten-free diet and the 
mucosal damage will reappear if gluten is reintroduced [2]. Extensive time-course studies 
have provided evidence that during gluten challenge an inflammatory process with a 
dose-dependent accumulation of intraepithelial lymphocytes (IELs) is followed by 
mucosal villous atrophy with crypt hyperplasia [3]. In untreated celiac disease the degree 
of malabsorption is determined by the length of the functionally impaired bowel and the 
presence of symptoms is noway related to the histological features of a proximal biopsy 
[3-5]. More recently, it was concluded that only patients with extensive and severe 
enteropathy will give evidence of steatorrhea and increased intestinal permeability[6]. 
Biopsy has thus remained the golden standard in measuring gluten-induced ill health. 
Previously a gluten challenge was part of the routine diagnostic procedure in children and 
a characteristic mucosal lesion reappeared in most patients within two years[2,7]. In 
gluten challenge studies, the amount of gluten in normal food has been estimated to be as 
high as 10-20 g per day[8-10].  A reduced daily gluten dose (2.5-5 g per day) during a 
gluten-free diet has still enabled mucosal healing in half of the patients [11]. Also some 
adults challenged with 2.5-5 g of gluten daily for three to 14 months have shown no 
significant changes in mucosal morphology [12]. These findings are in marked conflict 
with those from  a recent challenge study where it was shown that even a minimal dose of 
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50 mg gluten daily induced a significant mucosal deterioration [13]. Altogether, the 
patient groups in these studies have been rather small and no unequivocal conclusions 
can be drawn.  
 
A gluten-free diet is socially troublesome and expensive and research has shown  
compliance to the diet often to be poor [14]. Gluten contamination in a gluten-free diet is 
also difficult to avoid [15,16]. For these reasons many celiac patients have expressed a 
desire for other alternative or complementary treatments, less burdensome than a strict 
life-long gluten-free diet [17,18]. Any drug under evaluation as clinically effective and 
trusted by  celiac disease patients should significantly reduce or prevent gluten-induced 
mucosal injury. However, data are insufficient as to the amount of gluten to be used in a 
challenge study and for how long.  
 
In this pilot study we challenged adult celiac disease patients with gluten aiming to gain a 
clearer conception of the gluten amount needed to cause some mucosal deterioration but 
without inducing excessive ill health with a resultant dropout of trial subjects. We 
challenged treated celiac disease patients with low to moderate amounts of gluten for up 
to 12 weeks to establish whether a morphometrically measurable mucosal deterioration 
could be detected. We especially measured separately mucosal morphological change as 
villous height crypt depth ratio (Vh/CrD) and the inflammatory aspect in terms of density 
of mucosal IELs, both known to be sensitive continuous functional parameters of gluten 
ingestion in celiac disease. Further, we sought to establish whether the gluten-dependent 
serum antibody markers show seroconversions.   
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Methods 
Patients and study design 
Altogether 25 adult volunteers with previously diagnosed celiac disease were recruited 
for the gluten challenge study. Inclusion criteria comprised biopsy-proven celiac disease 
in patients aged 18-75 years adhering to a strict gluten-free diet for at least two years and 
being in clinical remission as judged by an interview, clinical examination and on-site 
rapid celiac autoantibody testing. Patients with a history of regular dietary transgressions, 
and those suffering from a condition carrying a risk at endoscopy, or using 
immunosuppressive medication were excluded. 
 
At the outset the symptoms or signs leading to the diagnosis of celiac disease, the 
duration of the gluten-free diet, family history of celiac disease and associated conditions 
were recorded. Upper gastrointestinal endoscopy with duodenal biopsies, laboratory 
analysis and clinical evaluation including gastrointestinal symptoms, were carried out at  
baseline and after the challenge. The complete challenge lasted 12 weeks (84 + 14 days). 
Furthermore, at 4 weeks (28 + 7 days) and 8 weeks (56 + 14 days) the clinical and 
serological assessments were repeated. The study patients were divided into two groups, 
those consuming a moderate (3-5 g) amount of gluten and those consuming a low (1-3 g) 
amount of gluten daily. Those who prematurely withdrew from the study were 
encouraged to undergo follow-up examinations immediately after the challenge was 
discontinued.  After the challenge all patients continued their normal gluten-free diet. 
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Gluten product and dietary assessment 
Each patient consumed 1.25-5 g of gluten (as a biscuit) daily during the challenge while 
otherwise continuing on a strict gluten-free diet. A verified amount of industrial gluten 
(Meelunie, Amsterdam, the Netherlands) was added to the baking mixture of the biscuits, 
and the mean daily gluten consumption of each patient was calculated. Consumption of 
the gluten product, changes in dietary habits and possible dietary transgressions were 
inquired at each visit and by regular telephone contacts. At baseline and at the end of the 
study a dietitian made a detailed dietary analysis by means of interview and a 4-day 
record of food intake.  
 
Small-bowel mucosal morphology and inflammation 
Up to seven small-bowel biopsy specimens were taken from the distal part of the 
duodenum upon upper gastrointestinal endoscopy; the specimens were evaluated by the 
same investigator without prior knowledge of the history or findings. At least three 
biopsies were processed and stained with hematoxylin-eosin and studied under light 
microscopy. Poorly oriented sections were discarded; when necessary, the samples were 
dissected repeatedly until they were of good quality. Morphometric analysis measuring 
Vh/CrD was made in well-oriented biopsy samples as previously described  [19], and a 
ratio < 2.0 was regarded as compatible with villous atrophy and crypt hyperplasia and 
indicative of active celiac disease. During the gluten-challenge, a decrease in Vh/CrD of 
0.5 or more was considered significant and equivalent to clinical glutensensitivity [20].   
The remaining biopsies were snap-frozen for immunohistochemical stainings. The 
specimens were freshly embedded in optimal temperature compound (OCT, Tissue-Tec, 
Miles Inc, Elkhart, IN, USA), snap-frozen in liquid nitrogen and stored at –70 oC. 
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Immunohistochemical studies were carried out on 5-µm-thick frozen sections. CD3+ 
IELs were stained with monoclonal antibody Leu-4 (Becton Dickinson, San Jose, CA, 
USA). IELs were counted with a x100 flat-field light microscope objective in randomly 
selected surface epithelium and the density of IELs expressed as cells/ millimetre of 
epithelium as previously described, the reference values being set at 37 cells/mm for 
CD3+ IELs [21]. After the gluten challenge an over 30% increase in IEL counts was 
considered significant and equivalent to clinical glutensensitivity [20]. In our laboratory 
the correlation coefficients for intraobserver variation for CD3+ IELs has been 0.95 and 
that for interobserver variation 0.92. 
 
Celiac serology 
Serum IgA class transglutaminase 2 (TG2)-antibodies were investigated by an enzyme-
linked immunosorbent assay (ELISA) according to manufacturer’s instructions 
(QUANTA Lite h-tTGIgA, INOVA, Diagnostics, Inc, CA, USA). The cut-off value for a 
positive antibody level was 20 IU. Serum IgA class endomysial antibodies (EMA) were 
determined by an indirect immunofluorescence method using human umbilical cord as 
substrate; a dilution of 1:5 or more was considered positive [22]. Positive sera were 
further diluted: 1:50, 1:100, 1:200, 1:500, 1:1000, 1:2000, 1:4000. We also determined a 
combination of serum IgA and IgG class deaminated gliadin peptide (DGP) antibodies 
(QUANTA Lite Celiac DPG Screen, INOVA Diagnostics) by ELISA, and values ≥20 IU 
were considered positive. None of the study subjects suffered from selective IgA 
deficiency. The change in antibody levels was considered clinically significant when 
antibodies seroconverted from negative to positive or when positive antibody levels 
increased and at least doubled during the gluten challenge. 
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Small-bowel mucosal TG2-targeted autoantibody deposits 
The small bowel mucosal TG2- specific autoantibody deposits were studied by direct 
immunofluorescence methods in frozen biopsy sections [20, 23-25]. From each patient 
altogether six unfixed, 5-µm-thick sections from frozen small-bowel specimens were 
processed, three for investigation of IgA deposits and three for double-color labelling for 
both IgA and TG2. IgA was detected by direct immunofluorescence using fluorescein 
isothiocyanate-labelled rabbit antibody against human IgA (Dako AS, Glostrup, 
Denmark) as previously described [23]. In celiac disease a clear subepithelial IgA 
deposition was found below the basement membrane along the villous and crypt 
epithelium and around mucosal vessels, in contrast to that observed in non-celiac 
samples, where only endogenous IgA is found inside plasma cells and epithelial cells. 
Sections were further double-stained for human IgA (green, as above) and for TG2 (red, 
monoclonal mouse antibody CUB7402, NeoMArers, Fremont, CA, USA, followed by 
rhodamine-conjugated anti-mouse immunoglobulin antibodies, Dako) to confirm that 
celiac-type IgA deposits co-localized with TG2. The occurrence of IgA deposits was 
graded semi-quantitatively according to their intensity along the basement membrane in 
the villous-crypt area as follows: negative (0), weak (+), moderate (++) and strong 
positive (+++). In cases where the intensity of the staining was patchy, it was graded 
from different areas and the mean value was given. All evaluations were carried out in 
blinded fashion without knowledge of disease history or laboratory findings. The 
correlation coefficients for both intraobserver and interobserver variations for the 
detection of presence or absence of TG2-specific IgA deposits have been 0.98 in our 
laboratory. An increase in the intensity of IgA-deposit staining after gluten challenge was 
considered indicative of clinical gluten-sensitivity. 
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Gastrointestinal symptoms 
Clinical symptoms appearing during the gluten challenge were semiquantatively 
classified into four categories- no symptoms, slight, moderate or severe symptoms- by 
means of interview and recorded at each visit.  
 
Statistics 
Quantitative data were expressed as medians and ranges or means and 95% confidence 
intervals (CI). Statistical differences were evaluated using Mann-Whitney test and 
Wilcoxon’s test or unpaired and paired t-test as appropriate, and all testing was two-
sided. Fisher’s exact test was used in cross-tabulations. The Pearson coefficient was used 
for correlation studies. P-values < 0.05 were considered statistically significant. All 
statistical testing was performed using SPSS version 16.0 (SPSS Inc., Chicago, IL, USA) 
 
Ethical considerations 
The study protocol was approved by the Ethics Committee of Tampere University 
Hospital. All subjects gave written informed consent.  
 
Results 
Altogether 25 adult celiac disease patients fulfilling the inclusion criteria were enrolled 
for the study (Table 1). At the time of the diagnosis, the majority (88%) had suffered 
from abdominal symptoms. When volunteering for this study, the patients had been a 
median of 11 years on a strict gluten-free diet, and all were in clinical remission.  
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At baseline in the current study, all patients except one had normal Vh/CrD ratios 
(median 2.9, range 1.3-4.2) on small-intestinal biopsy (Table 2). The mean density of 
CD3+ IELs was 63 cells/mm (range 23-146).  Altogether six patients had borderline 
positive celiac disease antibody levels (three had positive TG2 antibodies, two EMA and 
one DGP antibodies); in the rest all three antibodies were negative. When TG2-targeted 
autoantibodies were assessed at small-bowel mucosal level, moderate IgA-deposits were 
seen in two and faint in four patients. In the remaining 19 cases, mucosal TG2-
autoantibody depositions were negative at the beginning of the challenge study. 
 
Altogether four celiac disease patients belonging to the moderate gluten dose group 
discontinued the study due to abdominal symptoms shortly after the challenge was 
initiated (after three, eight, ten  and 23 days), and they were excluded from the final 
analyses. Celiac serology remained negative in all. The first two drop-outs with 
extremely brief gluten challenges underwent the follow-up endoscopy, and no small- 
bowel mucosal deterioration was evident.  
 
The remaining 21 patients comprised the final study population (Tables 2 and 3), for 
whom the gluten challenge lasted a median of 84 days (range 29-103 days) with an 
average of 3.1 g  daily gluten consumption (range 1.3-5.0 g/day). When the cohort was 
further divided according to the average daily gluten intake, ten patients belonged to the 
moderate-dose (3-5 g) and 11 to the low-dose (1-3 g) gluten challenge group (Tables 2 
and 3). In the moderate-dose group, three patients withdrew prematurely (after 29, 38 and 
61 days) by reason of abdominal symptoms such as diarrhea, vomiting and abdominal 
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pain; one patient discontinued at day 45 for personal reasons. Intended end-point 
examinations were carried out in all four cases immediately after cessation of the 
challenge. All celiac patients in the low-dose gluten challenge group completed the study 
as planned after 12 weeks’ challenge. Patients with a moderate gluten dose were thus 
more prone than those with a low dose to withdraw prematurely from the study 
(p=0.035). 
 
During the gluten challenge, a clinically significant decrease in Vh/CrD was found in 14 
(67%) out of the 21 celiac patients; seven were in the moderate and seven in the low 
gluten dose group (Table 2, Figures 1 and 2). The Vh/CrD in the moderate-dose group 
deteriorated from a mean 3.0 (95%CI 2.8-3.2) to 1.7 (95%CI 1.0-2.4) and in the low-dose 
group from 2.9 (95%CI 2.5-3.4) to 1.9 (95%CI 1.2-2.6), both changes being statistically 
significant (p=0.002 and p=0.016, respectively). The changes in Vh/CrD did not correlate 
with daily gluten intake (r= -0.138, p=0.552).  
 
In line with the morphological findings, a clinically significant change in the density of 
CD3+ IELs was seen in altogether 14 (67%) subjects; eight in the moderate-dose and six 
in the low-dose of (Table 2, Figures 3 and 4). In the moderate gluten dose group the IEL 
count increased significantly from a mean 49 cell/mm (95%CI 38-60) to 88 cell/mm 
(95%CI 70-106, p=0.001). In the low-dose group the increase did not reach statistical 
significance (from a mean 78 cell/mm [95%CI 56-100] to 98 cell/mm [95%CI 61-135], 
p=0.188). All in all, daily gluten intake did not correlate with increased inflammation 
(gluten intake vs. ∆CD3+ IEL count, r=0.251, p=0.273). 
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Altogether nine (43%) celiac disease patients, five in the moderate- and four in the low-
dose gluten challenge group, showed significant increases in TG2 antibody titers (Table 
3). The subjects consuming moderate doses of gluten evinced clearly higher TG2 
antibody titer responses than those consuming low doses; this was already seen after four 
weeks’ challenge (Figure 5). Interestingly, after the highest positive titer during the 
gluten challenge, the serum TG2 antibody levels tended to decrease even if gluten 
consumption continued (Figure 5). Serum EMA and DGP antibody titers were in line 
with TG2 antibody results; furthermore, after the gluten challenge all these three 
antibodies appeared in the serum simultaneously (data not shown). Small-bowel mucosal 
TG2-targeted autoantibody deposits generally followed the gluten-induced serological 
response in sera and morphological changes seen in the biopsy specimens (Tables 2 and 
3). 
 
At the outset, all subjects were free of gastrointestinal symptoms. Altogether 15 (71%) 
out of the 21 celiac disease patients experienced mild to moderate abdominal symptoms 
upon gluten challenge; eight of them (including the four withdrawing prematurely , see 
above) were from the moderate-dose and seven from the low-dose group (Table 2). None 
developed severe symptoms. Thirteen (87%) out of the 15 symptomatic patients also 
developed small-intestinal mucosal changes (significant decrease in Vh/CrD and/or 
increase in the density of CD3+ IELs). Of note, symptoms did not reveal four celiac 
disease patients having clinically significant gluten-induced small-bowel mucosal 
damage. 
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Discussion 
Twelve weeks’ gluten challenge with both moderate and low amounts of gluten sufficed 
to induce small-bowel mucosal morphological damage in the majority of volunteer 
treated celiac disease adults not, however, in all. An increase in the density of CD3+ IELs 
paralleled this phenomenon especially in the moderate-dose gluten challenge group. At 
the same time, moderate gluten doses triggered more gastrointestinal symptoms leading 
to premature withdrawals from the study. This suggests that in the 12-week time-frame 
smaller gluten doses of 1-3 g per day might be preferable to higher doses in order to 
obtain sufficient complete read-outs at the end of a challenge study.  
 
In this study, small-bowel mucosal Vh/CrD measurement seemed to be the most sensitive 
parameter in both moderate and low gluten doses in assessing gluten-induced damage in 
celiac disease. This conception is also in line with previous findings, where the Vh/CrD 
index has been used to show harmful effects of gluten in both short-term gluten 
challenges and long-term follow-up studies [8,13,26,27]. It is not surprising that the IEL 
count was a reliable marker for gluten toxicity only with moderate, but not with low 
gluten doses, as it has previously been shown that in celiac disease during a gluten-
challenge, IELs accumulate in the surface and crypt epithelium in a dose-dependent 
manner [3]. It is also important to note that even if the majority of celiac disease patients 
after gluten challenge yielded positive read-outs both in the Vh/CrD index and in the IEL 
count, there were some discrepant cases responding only with one or other parameter 
(Table 2). Marsh classification entailing six diagnostic categories (type 0-type 3c) has 
been widely used in the diagnostic work-up and follow-up of celiac disease [3]. Marsh 
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grades type 1-type 3c all indicate cursorily that small-bowel mucosal IEL density is 
increased (>40 IELs/100enterocytes), but different categories point more specifically to 
different morphological features (such as normal villous morphology, crypt hyperplasia 
or villous atrophy). Nonetheless the Marsh classification does not take into account minor 
gluten- induced mucosal changes (e.g. a significant decrease in Vh/CrD or increase in 
density of IELs within one Marsh grade) or discrepant results in Vh/CrD or IEL counts 
during a gluten challenge. It would thus be advisable in gluten challenge research 
projects, to use two separate continuous readout parameters in assessing gluten-
dependent functional mucosal changes, i.e. the morphological Vh/CrD and the 
inflammatory IEL changes, as opposed to applying a simplified grouped classification.  
 
Even if abdominal symptoms after the consumption of cereals do not generally constitute 
a specific marker of untreated celiac disease [28], gluten-induced gastrointestinal 
symptoms in our challenge study showed  high positive predictive value (87%) for small-
bowel mucosal injury in celiac disease patients. However, in 22% of the cases who 
developed significant small-intestinal damage, symptoms remained absent. It is widely 
known that many untreated celiac disease patients do not suffer from symptoms even if 
they have a manifest gluten-induced small-bowel mucosal lesion [29]. Furthermore, in 
some treated celiac disease patients, symptoms may disappear on a strict gluten-free diet 
despite continued ongoing mucosal villous atrophy [30,31]. Such persistent small-
intestinal villous atrophy in symptom-free patients clearly carries a risk of subsequent 
severe complications such as osteoporosis and malignancies [30]. This warrants caution 
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in relying solely on symptoms or other patient-related outcomes without small-bowel 
biopsies in gluten challenge research projects. 
 
In studies where a gluten challenge has been applied for diagnostic purposes in children 
on a normal daily gluten-containing diet (10-20 g daily), a small-bowel mucosal 
histological relapse has usually developed within three to twelve months in the majority 
of patients [8,9]. Seroconversion of EMA and TG2 antibodies is known to be a reliable 
predictor of histological relapse and antibody testing has helped in the timing of the 
biopsy [9]. In this study with low to moderate gluten doses, only 43% of the challenged 
adult celiac disease patients evinced a significant serological response. In line with earlier 
challenge studies, here all those who had increased serum autoantibodies during the 
challenge also developed small-bowel villous atrophy. However, at the same time 
serology missed nine cases with significant small-bowel mucosal changes (Tables 2 and 
3). These cases might have called for a longer gluten challenge period or higher gluten 
amounts. However, it is well-known that serology may fail to detect occasional slight 
dietary transgressions and incomplete mucosal healing [30,32,33], and therefore celiac 
serology is not always a reliable means of assessing gluten-induced harm. Furthermore, it 
is important to note that after the gluten challenge all three antibody – EMA, TG2 and 
DPG antibody – tests performed similar way, and recently introduced DPG antibody test 
was not superior to conventional serological assays. As small-bowel mucosal TG2-
specific autoantibody deposits have also been found in seronegative celiac patients and 
patients with early-stage celiac disease [23,24,34], it has been hypothesized that these 
mucosal autoantibodies might also appear early during a gluten challenge. In our study, 
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mucosal autoantibodies followed the morphological damage, and they added only little to 
the normal morphometrical measurements. It might be that after a short-term acute gluten 
challenge the distribution of mucosal autoantibody depositions is patchy, and single 
mucosal biopsies may not reveal the positivity.  It remains to be seen whether they will 
be of use at earlier time-points in the gluten challenge, but due to the invasive nature of 
small-bowel biopsies we were not able to take specimens on several occasions during the 
challenge.  
 
There were some celiac disease patients who did not respond in terms of any of the 
measured outcome variables during the 12 weeks’ gluten challenge. It is well-known that 
celiac patients show varying sensitivity to gluten and the process of mucosal deterioration 
may take years or even decades [35-37].  Furthermore, it should be remembered that the 
phenotype of the disease may vary in the same person over time; celiac patients suffering 
originally from abdominal symptoms at diagnosis may later experience only 
extraintestinal symptoms such as dermatitis herpetiformis when gluten is re-introduced 
into the diet [37]. These issues need to be taken into account when sample sizes in study 
cohorts are determined. 
 
At the baseline of the study, the majority of the treated celiac disease patients evinced 
increased densities of IELs and one patient even had villous atrophy with crypt 
hyperplasia despite adherent to a strict long-term gluten-free diet. According to the 
literature, such cases exist and it has been shown that even 80% of treated patients may 
have ongoing villous atrophy during a strict diet [38-40]. These persistent mucosal 
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changes might be due to constant residual gluten contamination in the food, which again 
would indicate that alternative treatment options would be desirable. 
 
Conclusions 
All in all, further studies are still needed to establish the optimal gluten dose on the other 
hand causing some small-bowel mucosal deterioration but without inducing excessive ill 
health. Our results suggest that in drug trials, the duration of the gluten challenge might 
be shorter than 12 weeks and the gluten dose could be an average of those used in the 
current study (approximately 3g). As there are always some celiac disease patients who 
will not respond within these conditions, sample sizes must be sufficiently large to ensure 
adequate statistical power for the study. The Vh/CrD index seemed to be the most 
reliable outcome measurement in both moderate and low gluten doses. Furthermore, it 
must be remembered that during a gluten challenge, some celiac patients may remain 
asymptomatic even if they develop manifest gluten-induced mucosal damage – this might 
in the long-run predispose these cases to celiac disease-related complications.   
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Figures  
 
Figure 1.  
 Changes in small bowel mucosal villous height and crypt depth ratios in moderate-dose 
group at baseline and at completion of the study.  
Figure 2. 
Changes in small bowel mucosal villous height and crypt depth ratios in low-dose group 
at baseline and at completion of the study. 
Figure 3. 
Changes in small bowel mucosal densities of CD3+ IELs in moderate-dose group at 
baseline and at completion of the study. 
Figure 4. 
Changes in small bowel mucosal densities of CD3+ IELs in low-dose group at baseline 
and at completion of the study. 
Figure 5- Changes in antibody levels 
Transglutaminase 2 (TG2) antibody levels at baseline, at 4 and 8 weeks, and at the end of 
the study. Closed squares indicate moderate daily gluten dose 3-5 g and open squares low 
gluten doses (1-3 g per day). 
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Tables  
 Table 1. Demographic data on the 25 celiac disease patients 
Variable  
Female; n 21 (81%) 
Age; median (range), years 49 (21-68) 
Reason for suspicion of celiac disease at diagnosis  
 Abdominal symptoms 23 (88%) 
 Anemia or malabsorption 16 (62%) 
 Extraintestinal manifestations* 9 (35%) 
 Screening in risk groups of celiac disease† 1 (4%) 
Duration of gluten free diet; median (range), years 11 (2-34) 
Family history of celiac disease, n 8 (31%) 
*tooth enamel hypoplasia, hypothyreosis, growth delay 
†family history of celiac disease 
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Table 2.  Effect of moderate (3-5g) and low (1-3g) amounts of gluten on small-
bowel mucosal villous height crypt depth ratio (Vh/CrD), densities of CD3+ 
intraepithelial lymphocytes (IELs) and gastrointestinal symptoms in treated celiac 
disease patients. Clinically significant changes between baseline (I) and 12 weeks’ 
follow-up examination (II) are marked in bold numbers. Complete challenge lasted 
12 weeks (84 + 14 days). 
 
No Mean  Duration of  Small-bowel biopsy  
 daily gluten Vh/CrD*  CD3+ IELs†  
Symptoms‡ 
 gluten 
intake (g) 
challenge 
(days) 
I II I II I II 
 
Moderate amounts of gluten daily 
    
1 5.0 29 2.8 0.8 33 88 0 ++ 
2 4.9   84 3.5 3.4 43 84 0 0 
3 4.9  38 2.9 1.3 64 128 0 ++ 
4 4.7  45 2.7 0.2 70 113 0 + 
5 4.1  61 3.0 3.5 41 56 0 ++ 
6 4.0  91 3.0 0.6 45 97 0 + 
7 3.6  91 2.8 1.4 42 125 0 0 
8 3.6  84 3.0 2.6 38 47 0 + 
9 3.4 88 3.8 2.3 69 83 0 + 
10 3.3  86 2.7 0.6 68 96 0 + 
         
Low amounts of gluten daily     
11 2.8 89 2.5 3.1 87 52 0 + 
12 2.7  84 3.0 0.6 87 117 0 0 
13 2.6  81 2.9 3.1 49 50 0 0 
14 2.4  85 2.7 1.9 146 271 0 + 
15 2.2  103 4.2 1.3 23 48 0 + 
16 2.1 93 1.3 0.1 130 99 0 + 
17 2.1  85 3.3 2.4 100 79 0 + 
18 2.1 84 2.9 1.7 75 78 0 0 
19 2.1 83 3.2 3.4 70 123 0 + 
20 1.4 77 3.4 3.0 41 87 0 ++ 
21 1.3 78 2.5 0.8 53 71 0 0 
         
Altogether positive outcome§, 
n (%)                           
14 (67%) 14 (67%) 15 (71%) 
         
* Abnormal ratio compatible with active celiac disease <2.0 
† Reference value for CD3+ IELs 37 cell ⁄mm 
‡ Symptoms graded as 0=no symptoms, +=mild symptoms, ++=moderate symptoms,  
§ Positive outcome reported when clinically significant changes appeared (>0.5 decrease 
in Vh/CrD, >30% increase in IEL densities) or when symptoms worsened. 
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Table 3.  Effect of moderate (3-5g) and low (1-3g) amounts of gluten on serum 
transglutaminase 2 (TG2) antibodies and small bowel mucosal TG2-targeted 
autoantibody deposits in treated celiac disease patients. Clinically significant 
changes between baseline (I) and 12 weeks’ follow-up examination (II) are marked 
in bold letters. Complete challenge lasted 12 weeks (84 + 14 days). 
 
 No Mean daily 
gluten intake  
Duration of 
gluten  
Serum TG2 
antibodies*  
Mucosal TG2 
antibody deposits† 
 (g) challenge 
(days) 
I II I II 
 
Moderate amounts of gluten daily 
  
1 5.0 29 10 319 0 +++ 
2 4.9   84 9 13 0 0 
3 4.9  38 5 10 0 + 
4 4.7  45 44 218 + +++ 
5 4.1  61 6 5 0 0 
6 4.0  91 21 263 + +++ 
7 3.6  91 6 47 0 ++ 
8 3.6  84 8 10 ++ + 
9 3.4 88 13 16 0 0 
10 3.3  86 18 229 + +++ 
       
Low amounts of gluten daily   
11 2.8 89 6 7 0 
 ++ 
12 2.7  84 7 111 0 ++ 
13 2.6  81 7 5 0 0 
14 2.4  85 12 88 0 ++ 
15 2.2  103 9 9 0 0 
16 2.1 93 16 94 ++ ++ 
17 2.1  85 9 8 0 0 
18 2.1 84 24 21 + + 
19 2.1 83 8 8 0 0 
20 1.4 77 10 13 0 + 
21 1.3 78 14 101 0 ++ 
       
Altogether positive outcome‡, n (%)                          9 (43%) 11 (52%) 
       
* Values of ≥20 IU considered positive 
† Graded as negative (0), weak (+), moderate (++) and strong positive (+++) 
‡ Positive outcome reported when serum antibody levels or intensity of mucosal 
   autoantibody deposits increased. 
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